Long-term survival in ovarian cancer

Neijt, J.P.; Huinink, W.W. ten Bokkel; Burg, M.E.L. van der; Oosterom, A.T. van; Willemse, Pax H.B.; Vermorken, Jan B.; Lindert, A.C.M. van; Heintz, A. Peter M.; Aartsen, E.J.; Lent, M. van; Trimbos, J. Baptist; Meijer, André J. De

doi:10.1016/0277-5379(91)90011-2

Cited by 192 publications

(39 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 Interestingly, we observed that in patients inoperable at first surgery (these patients underwent succesful IDS) and therefore endowed with a poor prognosis 25,26 the 5-year OS rate (54%) and the median OS (75 months) seem Days to: WBC Ͼ1 ϫ 10 9 /l 10.6 Ϯ 0.9 8.7 Ϯ 0.7 9.8 Ϯ 0. to be higher than those (5-year OS ranging from 22% to 35% with a median OS of 25 months) seen with standard chemotherapy. 25,26 Available data on HDC in patients cytoreduced at the time of IDS are scanty and mostly uninterpretable; 3,8,17 nevertheless, our data are in good keeping with the results reported by Legros et al, 8 and suggest that ovarian cancer patients with inoperable disease at diagnosis may still benefit from HDC if tumors are chemosensitive and optimal debulking can be performed by IDS. In this patient subset the extent of benefit seems even greater than in patients optimally cytoreduced at first surgery, although the very wide range of confidence intervals does not allow any definitive conclusions to be drawn.…”

Section: Discussionsupporting

confidence: 85%

High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results

Salerno

Ferrandina

Greggi

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results

Salerno

Ferrandina

Greggi

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Despite the established role of platinum-based combination chemotherapy in the treatment of ovarian cancer, resulting in prolonged disease-free survival even in patients with overt metastatic disease, unfortunately the majority of patients eventually will relapse (Neijt et al, 1991).…”

mentioning

confidence: 99%

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

et al. 2002

View full text Add to dashboard Cite

We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory ovarium cancer. One hundred and seven patients were entered on the study, 98 patients completed the induction therapy consisting of cisplatin at either 50 or 70 mg m 72 weekly for six administrations plus oral etoposide at a dose of 50 mg daily. Of these 98 patients, 38 had a platinum treatment-free interval of more than 12 months, 32 had an interval between 4 and 12 months, and 28 had progressed during or within 4 months after last platinum therapy. We assessed response rates and time to progression, and also response duration and survival. Analyses were done on the 98 evaluable patients. All 107 patients were considered evaluable for toxicity. Of the 38 patients with a treatment-free interval of more than 12 months, 92% responded, with 63% complete responses. The median progression-free survival in these patients was 14 months, and the median survival was 26 months. Of the 32 patients with an interval of 4 -12 months, 91% responded, with 31% complete responses, a median progression-free interval of 8 and a median overall survival of 16 months. Of the 28 patients with platinum-refractory disease, 46% as yet responded, with 29% complete responses, median progression-free interval of 5 and an overall survival of 13 months. Haematologic and non-haematologic, particularly renal toxicity and neurotoxicity, were notably mild. We conclude that this intensive regimen of weekly cisplatin plus daily etoposide is highly effective and well tolerated in patients with ovarian cancer relapsing after conventional platinum-based combination chemotherapy, including patients who have progressed during or within 4 months after platinum treatment.

show abstract

“…It has been debated whether the distinction between complete pathologic response and microscopic disease has a clinical relevance (16). In an early analysis of patients included in the Dutch ovarian cancer study group, Nejt et al (31) found that patients with microscopic disease had a survival similar to that of patients with complete pathological response. However, a long-term survival analysis of the Dutch study showed that the proportion of patients with complete pathologic response was 6O%, compared with 25% for patients with microscopic disease (31).…”

Section: Resultsmentioning

confidence: 99%

Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

Tropé¹,

Andersson²,

Björkholm³

et al. 1996

Acta Oncologica

View full text Add to dashboard Cite

Long-term survival in ovarian cancer

Cited by 192 publications

References 4 publications

High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results

High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

Doxorubicin-Melphalan with and Without Cisplatin in Advanced Ovarian Cancer: Ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group

Contact Info

Product

Resources

About